​

aTyr Pharma (ATYR) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChartTranscripts

ATYR Stock Forecast

aTyr Pharma (ATYR) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $5.13, with a high of $17.00 and a low of $1.00. This represents a 584.00% increase from the last price of $0.75.

- $4 $8 $12 $16 $20 High: $17 Avg: $5.13 Low: $1 Last Closed Price: $0.75

ATYR Stock Rating

aTyr Pharma stock's rating consensus is Hold, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (40.00%), 3 Hold (60.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 5 0 3 2 Strong Sell Sell Hold Buy Strong Buy

ATYR Price Target Upside V Benchmarks

TypeNameUpside
StockaTyr Pharma584.00%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-44
Avg Price Target-$5.13$5.13
Last Closing Price$0.75$0.75$0.75
Upside/Downside-584.00%584.00%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 25218--11
Oct, 25218--11
Sep, 2547---11
Aug, 2547---11
Jul, 2547---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 15, 2025Brian AbrahamsRBC Capital$1.50$1.0247.06%100.00%
Sep 15, 2025Derek ArchilaWells Fargo$1.00$1.02-1.96%33.33%
Sep 15, 2025Faisal KhurshidLeerink Partners$1.00$1.02-1.96%33.33%
Aug 22, 2025Roger SongJefferies$17.00$5.35217.76%2166.67%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 15, 2025RBC CapitalSector Performdowngrade
Sep 15, 2025H.C. WainwrightBuyNeutraldowngrade
Sep 15, 2025Cantor FitzgeraldNeutraldowngrade
Aug 22, 2025JefferiesBuyBuyhold
Oct 29, 2024H.C. WainwrightBuyBuyhold
Oct 21, 2024Piper SandlerOverweightOverweighthold
Oct 04, 2024Wells FargoOverweightinitialise
Sep 05, 2024JefferiesBuyinitialise

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.77$-1.77$-1.60$-0.94-----
Avg Forecast$-2.17$-1.79$-1.82$-0.93$-0.91$-0.81$-0.60$0.33$1.70
High Forecast$-2.14$-1.77$-1.82$-0.93$-0.90$-0.77$-0.60$0.33$1.70
Low Forecast$-2.21$-1.83$-1.82$-0.93$-0.92$-0.86$-0.60$0.33$1.70
Surprise %-18.43%-1.12%-12.09%1.08%-----

Revenue Forecast

$0 $70M $140M $210M $280M $350M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.46M-$10.39M$353.00K-----
Avg Forecast$8.53M$2.16M$357.14K$421.20K$241.11K$2.85M$37.45M$167.72M$335.76M
High Forecast$8.66M$2.19M$357.14K$421.20K$275.56K$2.85M$37.45M$167.72M$335.76M
Low Forecast$8.46M$2.14M$357.14K$421.20K$229.63K$2.85M$37.45M$167.72M$335.76M
Surprise %22.52%-2808.08%-16.19%-----

Net Income Forecast

$-150M $-100M $-50M $0 $50M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-16.22M$-33.77M$-45.34M$-50.39M-----
Avg Forecast$-116.15M$-96.13M$-97.56M$-50.07M$-48.96M$-43.48M$-32.36M$17.69M$90.90M
High Forecast$-114.86M$-95.07M$-97.56M$-50.07M$-48.42M$-41.12M$-32.36M$17.69M$90.90M
Low Forecast$-118.37M$-97.97M$-97.56M$-50.07M$-49.50M$-46.32M$-32.36M$17.69M$90.90M
Surprise %-86.03%-64.87%-53.53%0.64%-----

ATYR Forecast FAQ

Is aTyr Pharma stock a buy?

aTyr Pharma stock has a consensus rating of Hold, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that aTyr Pharma is a neutral investment for most analysts.

What is aTyr Pharma's price target?

aTyr Pharma's price target, set by 5 Wall Street analysts, averages $5.13 over the next 12 months. The price target range spans from $1 at the low end to $17 at the high end, suggesting a potential 584.00% change from the previous closing price of $0.75.

How does aTyr Pharma stock forecast compare to its benchmarks?

aTyr Pharma's stock forecast shows a 584.00% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for aTyr Pharma over the past three months?

  • November 2025: 18.18% Strong Buy, 9.09% Buy, 72.73% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 18.18% Strong Buy, 9.09% Buy, 72.73% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 36.36% Strong Buy, 63.64% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is aTyr Pharma’s EPS forecast?

aTyr Pharma's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.91, marking a -3.19% decrease from the reported $-0.94 in 2023. Estimates for the following years are $-0.81 in 2025, $-0.6 in 2026, $0.33 in 2027, and $1.7 in 2028.

What is aTyr Pharma’s revenue forecast?

aTyr Pharma's average annual revenue forecast for its fiscal year ending in December 2024 is $241.11K, reflecting a -31.70% decrease from the reported $353K in 2023. The forecast for 2025 is $2.85M, followed by $37.45M for 2026, $167.72M for 2027, and $335.76M for 2028.

What is aTyr Pharma’s net income forecast?

aTyr Pharma's net income forecast for the fiscal year ending in December 2024 stands at $-48.96M, representing a -2.84% decrease from the reported $-50.389M in 2023. Projections indicate $-43.481M in 2025, $-32.365M in 2026, $17.69M in 2027, and $90.9M in 2028.